N‑(2-Aminophenyl)-benzamide Inhibitors of Class I HDAC Enzymes with Antiproliferative and Antifibrotic Activity

• Published in: Journal of medicinal chemistry 2023-10, Vol.66 (20), p.14357-14376
• Main Authors: Gerokonstantis, Dimitrios Triantafyllos, Mantzourani, Christiana, Gkikas, Dimitrios, Wu, Kai-Chen, Hoang, Huy N., Triandafillidi, Ierasia, Barbayianni, Ilianna, Kanellopoulou, Paraskevi, Kokotos, Alexandros C., Moutevelis-Minakakis, Panagiota, Aidinis, Vassilis, Politis, Panagiotis K., Fairlie, David P., Kokotos, George
• Format: Article
• Language: English
• ISSN: 0022-2623; 1520-4804
• DOI: 10.1021/acs.jmedchem.3c01422

Inhibitors of histone deacetylases (HDACs) have received special attention as novel anticancer agents. Among various types of synthetic inhibitors, benzamides constitute an important class, and one is an approved drug (chidamide). Here, we present a novel class of HDAC inhibitors containing the N-(2-aminophenyl)-benzamide functionality as the zinc-binding group linked to various cap groups, including the amino acids pyroglutamic acid and proline. We have identified benzamides that inhibit HADC1 and HDAC2 at nanomolar concentrations, with antiproliferative activity at micromolar concentrations against A549 and SF268 cancer cell lines. Docking studies shed light on the mode of binding of benzamide inhibitors to HDAC1, whereas cellular analysis revealed downregulated expression of EGFR mRNA and protein. Two benzamides were investigated in a mouse model of bleomycin-induced pulmonary fibrosis, and both showed efficacy on a preventative dosing schedule. N-(2-Aminophenyl)-benzamide inhibitors of class I HDACs might lead to new approaches for treating fibrotic disorders.